{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,26]],"date-time":"2025-12-26T14:49:54Z","timestamp":1766760594377,"version":"build-2065373602"},"reference-count":5,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2018,11,1]],"date-time":"2018-11-01T00:00:00Z","timestamp":1541030400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,11,1]],"date-time":"2018-11-01T00:00:00Z","timestamp":1541030400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"vor","delay-in-days":731,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","cysticfibrosisjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Cystic Fibrosis"],"published-print":{"date-parts":[[2018,11]]},"DOI":"10.1016\/j.jcf.2018.08.003","type":"journal-article","created":{"date-parts":[[2018,8,29]],"date-time":"2018-08-29T08:48:44Z","timestamp":1535532524000},"page":"e48-e50","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Use of telavancin in adolescent patients with cystic fibrosis and prior intolerance to vancomycin: A case series"],"prefix":"10.1016","volume":"17","author":[{"given":"Adam T.","family":"Bernstein","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Margaret W.","family":"Leigh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jennifer L.","family":"Goralski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"suffix":"Jr","given":"Charles R.","family":"Esther","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cameron J.","family":"McKinzie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"author":"Cystic Fibrosis Foundation Patient Registry","key":"10.1016\/j.jcf.2018.08.003_bb0005"},{"key":"10.1016\/j.jcf.2018.08.003_bb0010","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1002\/ppul.23132","article-title":"Utilization of Antibiotics for Methicillin-Resistant Staphylococcus aureus Infection in Cystic Fibrosis","volume":"50","author":"JT","year":"2015","journal-title":"Pediatr Pulmonol"},{"year":"2017","series-title":"South San Francisco, CA","author":"Vibativ\u00ae [package insert]","key":"10.1016\/j.jcf.2018.08.003_bb0015"},{"issue":"1","key":"10.1016\/j.jcf.2018.08.003_bb0020","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1093\/cid\/ciq031","article-title":"Telavancin versus Vancomycin for Hospital-Acquired Pneumonia due to Gram-positive Pathogens","volume":"52","author":"Rubinstein","year":"2011","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jcf.2018.08.003_bb0025","article-title":"Nephrotoxicity with vancomycin in the pediatric population: a systematic review and meta-analysis","author":"Fiorito","year":"2017","journal-title":"Petiatr Infect Dis J"}],"container-title":["Journal of Cystic Fibrosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S156919931830746X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S156919931830746X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T21:39:16Z","timestamp":1761601156000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S156919931830746X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11]]},"references-count":5,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2018,11]]}},"alternative-id":["S156919931830746X"],"URL":"https:\/\/doi.org\/10.1016\/j.jcf.2018.08.003","relation":{},"ISSN":["1569-1993"],"issn-type":[{"type":"print","value":"1569-1993"}],"subject":[],"published":{"date-parts":[[2018,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Use of telavancin in adolescent patients with cystic fibrosis and prior intolerance to vancomycin: A case series","name":"articletitle","label":"Article Title"},{"value":"Journal of Cystic Fibrosis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcf.2018.08.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier B.V. on behalf of European Cystic Fibrosis Society.","name":"copyright","label":"Copyright"}]}}